News
Crossed
Your contact person

Jan Phillip Denkers
Manager PR & Communications
T +49.40.593 62 61-23
E-Mail

Filter reset

Crown Bioscience to Acquire Indivumed’s Service Business

Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has announced it has entered into an agreement to acquire the IndivuServ business unit of Indivumed …
Dr. Christian Regenbrecht, CEO of CELLphenomics (2nd from left) and Prof. Dr. Hartmut Juhl, CEO and founder of Indivumed (2nd from right) are pleased about the agreed partnership. ( Picture: © Indivumed)

Biotech & Pharma

Indivumed and CELLphenomics Announce Partnership

Indivumed GmbH (“Indivumed”) and CELLphenomics GmbH (“CELLphenomics”) today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic …

Biotech & Pharma

Indivumed Celebrates 20th Anniversary

Indivumed GmbH (“Indivumed”) today celebrated the company’s 20th anniversary milestone. Founded in Hamburg, Germany on April 5, 2002, Indivumed has rapidly expanded to become a leading innovator in …
Senator of Economics Affairs Michael Westhagemann (left) and Ralf Sommer, CEO of the Hamburg Investment and Development Bank (right) hand over the notification of funding to Indivumed CEO Prof. Dr. Hartmut Juhl (Image: ©BVM)

Biotech & Pharma, Funding & Competition, LSN

Accelerated drug development and personalised treatments …

Indivumed GmbH is a biotech company with international activities and representative offices in the US, Japan, Italy and Brasil. It cooperates with numerous international research institutions and …
Indivumed is using nRavel™ for target discovery and drug development programs. (Picture: ©Jackie Niam/stock.adobe.com)

Biotech & Pharma, Digitalisation

Indivumed Launches the nRavel AI Platform

Indivumed GmbH (“Indivumed”) today announced the launch of nRavel™, a unique AI discovery platform for oncology and precision medicine. The platform combines IndivuType’s deep multi-omics data with …
New Entity to Develop Therapeutics Targeting RAS Pathway Mutations in Colorectal Cancer (Picture: © Indivumed GmbH)

Biotech & Pharma, Digitalisation, Research, Academia & Universities

Indivumed Joins KHR Biotech

Indivumed GmbH (“Indivumed”) CEO Dr. Hartmut Juhl and University Medical Center Mainz Professor Krishnaraj Rajalingam today announced Indivumed will be joining the newly formed KHR Biotech GmbH (“KHR …

Biotech & Pharma

Indivumed Announces Expansion

Indivumed GmbH (“Indivumed”) announced today the founding of Ix Therapeutics GmbH (“Ix Therapeutics”), a joint venture with Xlife Sciences AG (“Xlife Sciences”), which marks Indivumed’s expansion into …
Photo: Indivumed GmbH

Biotech & Pharma, MedTech, Research, Academia & Universities

Indivumed’s multi-omics database IndivuType

More than 200 participants from around the globe, including fourteen of the top 20 pharma companies, numerous biotech companies, and members from leading academic cancer research institutions, were …